A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Condition:   Neoplasms, Ovarian Interventions:   Drug: MORAb-202;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Topotecan Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials